INT132971

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2005
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 5
Total Number 7
Disease Relevance 3.98
Pain Relevance 1.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (IGF1) extracellular space (IGF1) extracellular region (IGF1)
Anatomy Link Frequency
blood 2
chondrocytes 2
hepatocytes 2
liver 2
IGF1 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 86 99.68 Very High Very High Very High
Dopamine 90 99.44 Very High Very High Very High
Somatostatin 66 99.08 Very High Very High Very High
cytokine 22 98.92 Very High Very High Very High
rheumatoid arthritis 77 94.92 High High
Inflammation 31 88.16 High High
antagonist 7 87.80 High High
tolerance 5 82.72 Quite High
Arthritis 12 82.00 Quite High
Clonidine 2 81.08 Quite High
Disease Link Frequency Relevance Heat
Prolactinoma 98 100.00 Very High Very High Very High
Cancer 119 98.82 Very High Very High Very High
Appetite Loss 10 96.88 Very High Very High Very High
Aging 2 96.12 Very High Very High Very High
Rheumatoid Arthritis 77 94.92 High High
Insulin Resistance 4 94.08 High High
Cardiovascular Disease 1 92.76 High High
Malabsorption Syndromes 2 90.64 High High
Liver Disease 4 89.64 High High
Pituitary Cancer 40 88.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Another approach was described by De Ceuninck et al [55], who noted that disruption of IGF-1 binding to the inhibitory binding proteins via small molecules, resulting in the release of free IGF-1, restores the anabolic response of human chondrocytes.
Negative_regulation (disruption) of Localization (release) of IGF-1 in chondrocytes
1) Confidence 0.42 Published 2006 Journal BMC Complement Altern Med Section Body Doc Link PMC1456997 Disease Relevance 0.16 Pain Relevance 0.08
In children with decreased IGF-I secretion and normal GH peak (both in nocturnal profile and after pharmacological stimulation), IGF-I generation test was performed after exclusion of other causes of IGF-I deficiency, not related to GH secretion disorders and GH action (like malabsorption syndromes, liver diseases, malnutrition, other severe chronic diseases).
Negative_regulation (decreased) of Localization (secretion) of IGF-I in liver associated with appetite loss, liver disease, malabsorption syndromes and chronic disease
2) Confidence 0.37 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.36 Pain Relevance 0.08
In all the children IGF-I and IGFBP-3 secretion was measured in a single blood sample during in morning hours.
Negative_regulation (measured) of Localization (secretion) of IGF-I in blood
3) Confidence 0.37 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.05 Pain Relevance 0
Progressive decline in the secretion of growth hormone (GH) and its principal circulating and tissue mediator, insulin-like growth factor-1 (IGF-I), is one of the key pathophysiological mechanisms contributing to the cachexia of normal aging [5].
Negative_regulation (decline) of Localization (secretion) of insulin-like growth factor-1 associated with appetite loss and aging
4) Confidence 0.25 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206381 Disease Relevance 1.28 Pain Relevance 0.50
More recently, it has been suggested that a sst ligand may also act peripherally on the GH/IGF-1 axis by binding to somatostatin receptors on peripheral organs, such as hepatocytes in the liver, to inhibit the secretion of IGF-1 [92].
Negative_regulation (inhibit) of Localization (secretion) of IGF-1 in hepatocytes associated with somatostatin
5) Confidence 0.21 Published 2010 Journal BMC Endocr Disord Section Body Doc Link PMC2887860 Disease Relevance 0.49 Pain Relevance 0.38
Furthermore, because the efficacy of pegvisomant is not dependent on tumor somatostatin receptor expression, pegvisomant effectively inhibits IGF-1 secretion in patients who are non- or partial responders to somatostatin analogues.
Negative_regulation (inhibits) of Localization (secretion) of IGF-1 associated with cancer and somatostatin
6) Confidence 0.16 Published 2010 Journal BMC Endocr Disord Section Body Doc Link PMC2887860 Disease Relevance 0.86 Pain Relevance 0.60
IGF-I levels should be followed in all patients with prolactinoma, even in those with normal basal GH concentrations, because of the possibility of GH co-secretion.
Spec (possibility) Negative_regulation (possibility) of Localization (co-secretion) of IGF-I associated with prolactinoma
7) Confidence 0.07 Published 2005 Journal Acta Paediatr. Section Abstract Doc Link 16421054 Disease Relevance 0.77 Pain Relevance 0.30

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox